RESUMEN
MS and endocrine dysfunction(s) are common well-recognized complications after HSCT. We retrospectively analyzed our data on 160 patients with a median age at transplant of five yr (0.3-23), who had been followed for a median of seven yr (range 3-18) at Nationwide Children's Hospital after transplant. Dyslipidemia and MS were seen in 13% and 7.5% patients, respectively, and 58% of these patients were <20 yr of age. Twelve patients met the criteria for diagnosis of MS, but four of these did not meet the International Diabetic Federation or WHO criteria. Variation in the diagnostic criteria for MS leading to underdiagnosis is discussed. Female gonadal failure (27%) and hypothyroidism (21%) were the most common endocrine dysfunctions, followed by short stature and GH deficiency (17%) each. TBI and younger age at HSCT were associated with the highest burden of long-term effects, and female sex was more significantly associated with MS-related dysfunction (p < 0.05). Uniform diagnostic criteria for MS and close follow-up after transplant are important for the early diagnosis and management of these late effects, thereby improving the overall quality of life of these patients.
Asunto(s)
Enfermedades del Sistema Endocrino/etiología , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Síndrome Metabólico/complicaciones , Síndrome Metabólico/etiología , Adolescente , Adulto , Niño , Preescolar , Enfermedades del Sistema Endocrino/complicaciones , Femenino , Humanos , Lactante , Masculino , Análisis Multivariante , Resultado del Tratamiento , Adulto JovenRESUMEN
Matched sibling donor hematopoietic stem cell transplantation is the standard of care for severe aplastic anemia, with an overall survival of 80% to 90%. Only 60% to 70% of patients respond to treatment with immunosuppressive therapy. The main life threatening complications are infections, graft failure, and graft versus host disease. A 10-year-old patient with severe aplastic anemia underwent matched sibling donor hematopoietic stem cell transplantation, but developed sudden onset of fatal multiorgan failure on day +12. The cause of death was found only after autopsy.
Asunto(s)
Anemia Aplásica/cirugía , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Mucormicosis/complicaciones , Insuficiencia Multiorgánica/etiología , Rhizomucor , Anfotericina B/uso terapéutico , Niño , Femenino , Humanos , Mucormicosis/tratamiento farmacológico , Pirimidinas/uso terapéutico , Triazoles/uso terapéutico , VoriconazolRESUMEN
BACKGROUND: Infantile Krabbe's disease produces progressive neurologic deterioration and death in early childhood. We hypothesized that transplantation of umbilical-cord blood from unrelated donors before the development of symptoms would favorably alter the natural history of the disease among newborns in whom the disease was diagnosed because of a family history. We compared the outcomes among these newborns with the outcomes among infants who underwent transplantation after the development of symptoms and with the outcomes in an untreated cohort of affected children. METHODS: Eleven asymptomatic newborns (age range, 12 to 44 days) and 14 symptomatic infants (age range, 142 to 352 days) with infantile Krabbe's disease underwent transplantation of umbilical-cord blood from unrelated donors after myeloablative chemotherapy. Engraftment, survival, and neurodevelopmental function were evaluated longitudinally for four months to six years. RESULTS: The rates of donor-cell engraftment and survival were 100 percent and 100 percent, respectively, among the asymptomatic newborns (median follow-up, 3.0 years) and 100 percent and 43 percent, respectively, among the symptomatic infants (median follow-up, 3.4 years). Surviving patients showed durable engraftment of donor-derived hematopoietic cells with restoration of normal blood galactocerebrosidase levels. Infants who underwent transplantation before the development of symptoms showed progressive central myelination and continued gains in developmental skills, and most had age-appropriate cognitive function and receptive language skills, but a few had mild-to-moderate delays in expressive language and mild-to-severe delays in gross motor function. Children who underwent transplantation after the onset of symptoms had minimal neurologic improvement. CONCLUSIONS: Transplantation of umbilical-cord blood from unrelated donors in newborns with infantile Krabbe's disease favorably altered the natural history of the disease. Transplantation in babies after symptoms had developed did not result in substantive neurologic improvement.
Asunto(s)
Desarrollo Infantil , Trasplante de Células Madre de Sangre del Cordón Umbilical , Sangre Fetal/trasplante , Leucodistrofia de Células Globoides/terapia , Encéfalo/anatomía & histología , Progresión de la Enfermedad , Electroencefalografía , Potenciales Evocados , Femenino , Galactosilceramidasa/líquido cefalorraquídeo , Galactosilceramidasa/metabolismo , Supervivencia de Injerto , Crecimiento , Prueba de Histocompatibilidad , Humanos , Lactante , Conducta del Lactante , Recién Nacido/crecimiento & desarrollo , Leucodistrofia de Células Globoides/mortalidad , Leucodistrofia de Células Globoides/fisiopatología , Estudios Longitudinales , Masculino , Destreza Motora , Trastornos de la Destreza Motora/etiología , Conducción Nerviosa , Análisis de Supervivencia , Acondicionamiento Pretrasplante , Resultado del TratamientoRESUMEN
BACKGROUND: Bone marrow (BM) is an excellent source of mesenchymal stem cells (MSC) which can be expanded in vitro for further use. However, large volumes of BM specimens are not routinely available. We hypothesized that the normally discarded BM collection kits might be a convenient source of large numbers of MSC. METHODS: Marrow specimens were isolated from used Fenwal collection kits. Purified mononuclear cells (MNC) were screened by multiparameter flow cytometry to identify MSC, which were later expanded by in vitro culture. Immunophenotyping and differentiation assays were performed initially and at subculture. Both fresh and frozen BM were tested. RESULTS: An average of 9.62E+08 MNC were collected. In this, a cell population was identified that was CD44+, CD73+, CD90+ and CD105+, but negative for hematopoietic markers. This population represented on average 0.015% of the total BM MNC fraction, or on average 1 in 6,666 MNC. The population was considered to be MSC based on its immunophenotype profile, suppressive ability in mixed lymphocyte cultures, morphology, and ability to differentiate into bone and fat cells. CONCLUSIONS: This study demonstrates that large numbers of MSC can be obtained from the normally discarded collection devices following harvest of BM for clinical transplant. This novel method offers potential for obtaining large numbers of MSC for potential therapeutic or investigational purposes following their in vitro expansion.
Asunto(s)
Médula Ósea , Separación Celular/métodos , Células Madre Mesenquimatosas/citología , Células Madre Mesenquimatosas/inmunología , Adulto , Recuento de Células , Proliferación Celular , Células Cultivadas , Niño , Femenino , Humanos , Inmunofenotipificación , Prueba de Cultivo Mixto de Linfocitos , Masculino , Persona de Mediana EdadAsunto(s)
Rayos gamma/efectos adversos , Trasplante de Células Madre Mesenquimatosas , Células Madre Mesenquimatosas/enzimología , Células Madre Multipotentes/enzimología , Traumatismos Experimentales por Radiación/terapia , Superóxido Dismutasa/metabolismo , Animales , Femenino , Ingeniería Genética , Ratones , Ratones Endogámicos BALB C , Traumatismos Experimentales por Radiación/enzimología , Traumatismos Experimentales por Radiación/genética , Superóxido Dismutasa/genética , Irradiación Corporal TotalRESUMEN
Osteopetrosis (OP) is a clinically and genetically heterogeneous disorder characterized by increased bone density. Associations between OP and other clinical entities are rare but include muscular degeneration, Dandy-Walker syndrome, craniosynostosis, and poikiloderma. Infantile OP has also been diagnosed in a group of infants with neuronal storage disease. An association between OP and juvenile xanthogranuloma (JXG) has never been previously reported. Herein we present a case of an intermediate form of OP in a newborn who presented with hepatosplenomegaly and pancytopenia. Histologic evaluation of a bone marrow biopsy demonstrated abnormally thickened bony trabeculae. A liver biopsy demonstrated prominent expansion of portal areas by a histiocytic infiltrate expressing CD45, CD14, CD68, CD163, factor XIIIa, and fascin, while the biopsy was negative for S100 and CD1a. These findings were those associated with JXG. Genetic testing demonstrated a mutation involving the Pleckstrin homology domain-containing family M member 1 ( PLEKHM1 ) gene. A different mutation in this gene has been previously reported in one other patient with OP. Our case is the 2nd reported case with PLEKHM1 mutation in a patient with a mild form of OP. It also demonstrates the 1st reported occurrence of OP concomitantly with JXG.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/genética , Glicoproteínas de Membrana/genética , Osteopetrosis/complicaciones , Osteopetrosis/genética , Xantogranuloma Juvenil/complicaciones , Xantogranuloma Juvenil/genética , Proteínas Relacionadas con la Autofagia , Biopsia , Humanos , Recién Nacido , Masculino , Osteopetrosis/patología , Xantogranuloma Juvenil/patologíaRESUMEN
The Cord Blood Transplantation Study (COBLT), sponsored by the National Heart, Lung, and Blood Institute, is a phase II multicenter study designed to evaluate the use of cord blood in allogeneic transplantation. In this report, we evaluated the outcomes of cord blood transplantation in 69 patients with lysosomal and peroxisomal storage diseases. Patients with mucopolysaccharidoses I to III, mucolipidoses (ML) II (n = 36), adrenoleukodystrophy (n = 8), metachromatic leukodystrophy (n = 6), Krabbe disease (n = 16), and Tay-Sachs disease (n = 3) were enrolled between August 1999 and June 2004. All patients received the same preparative regimen, graft-versus-host disease (GVHD) prophylaxis, and supportive care. End points included survival, engraftment, GVHD, and toxicity. Sixty-nine patients (64% men; 81% white) with a median age of 1.8 years underwent transplantation with a median cell dose of 8.7 x 10(7)/kg. One-year survival was 72% (95% confidence interval, 61%-83%). The cumulative incidence of neutrophil engraftment by day 42 was 78% (95% confidence interval, 67%-87%) at a median of 25 days. Grade II to IV acute GVHD occurred in 36% of patients. Cord blood donors are readily available for rapid transplantation. Cord blood transplantation should be considered as frontline therapy for young patients with lysosomal and peroxisomal storage diseases.
Asunto(s)
Trasplante de Células Madre de Sangre del Cordón Umbilical/mortalidad , Enfermedad Injerto contra Huésped/mortalidad , Enfermedades por Almacenamiento Lisosomal/mortalidad , Acondicionamiento Pretrasplante , Niño , Preescolar , Trasplante de Células Madre de Sangre del Cordón Umbilical/efectos adversos , Supervivencia sin Enfermedad , Femenino , Enfermedad Injerto contra Huésped/prevención & control , Humanos , Lactante , Enfermedades por Almacenamiento Lisosomal/terapia , Masculino , Estudios Retrospectivos , Tasa de Supervivencia , Acondicionamiento Pretrasplante/mortalidad , Trasplante HomólogoRESUMEN
A non-total body irradiation-containing preparative regimen was studied in young children (<4 years old) undergoing unrelated donor cord blood transplantation as part of the Cord Blood Transplantation trial for the treatment of acute lymphoblastic leukemia (n = 14), acute myeloid leukemia (n = 13), undifferentiated leukemia (n = 1), juvenile myelomonocytic leukemia (n = 2), and myelodysplastic syndromes (n = 2). Donor/recipient HLA matching based on low-/intermediate-resolution molecular typing for HLA-A and -B and high-resolution HLA-DRB1 typing was 5/6 or 6/6 (n = 21) or 4/6 (n = 11). The preparative therapy consisted of busulfan, melphalan, and antithymocyte globulin, with cyclosporine and corticosteroids for graft-versus-host disease (GVHD) prophylaxis. The median age was 1.6 years (range, 0.5-3.9 years), and the median weight was 10.5 kg (range, 5.8-19.5 kg). Cord blood grafts contained a median of 10.7 x 10 7 nucleated cells per kilogram (range, 4.6-29.2) and 2.6 x 10(5) CD34+ cells per kilogram (range, 0.7-8.3). The cumulative incidence (CINC) of neutrophil recovery (absolute neutrophil count >500/microL) at day 42 was 0.59 (95% confidence interval [CI], 0.44-0.78) at a median of 31 days (range, 23-55 days). The CINC and Kaplan-Meier estimates of platelet engraftment at day 180 were 0.53 (95% CI, 0.34-0.69) and 0.82 (95% CI, 0.61-1.00), respectively. CINC estimates of grade III/IV acute GVHD at day 100 and chronic GVHD at 1 year were 0.25 (95% CI, 0.09-0.41) and 0.26 (95% CI, 0.09-0.44), respectively. The CINC estimate of relapse was 0.31 (95% CI, 0.16-0.47) at 2 years. With a median follow-up of 27.8 months (range, 23.4-46.7 months), the probability of survival at 1 year was 0.47 (95% CI, 0.30-0.64). A preparative regimen containing a busulfan/melphalan/antithymocyte globulin preparative regimen is well tolerated in the setting of unrelated donor cord blood transplantation for childhood leukemia and can serve as a platform preparative regimen for intensifying host immunosuppression and antileukemic therapy to allow for improved engraftment and improved relapse-free survival.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Trasplante de Células Madre de Sangre del Cordón Umbilical , Leucemia/mortalidad , Leucemia/terapia , Suero Antilinfocítico/administración & dosificación , Antineoplásicos Alquilantes/administración & dosificación , Busulfano/administración & dosificación , Preescolar , Trasplante de Células Madre de Sangre del Cordón Umbilical/mortalidad , Supervivencia sin Enfermedad , Femenino , Supervivencia de Injerto , Enfermedad Injerto contra Huésped/mortalidad , Prueba de Histocompatibilidad , Humanos , Inmunosupresores/administración & dosificación , Lactante , Recién Nacido , Masculino , Melfalán/administración & dosificación , Estudios Retrospectivos , Acondicionamiento Pretrasplante/métodos , Irradiación Corporal TotalRESUMEN
The purpose of this study was to compare transplantation outcomes in patients with hematologic malignancies who received marrow grafts from either phenotypically matched unrelated, one-antigen-mismatched unrelated, or highly human leukocyte antigen (HLA)-disparate family donors. Between 1993 and 2000, 139 patients underwent transplantation from unrelated donors (81 matched and 58 mismatched) and 48 patients received marrow grafts from family donors that were mismatched at 2, 3, or 4 of 8 HLA loci. All patients received a standardized conditioning regimen and a graft-versus-host disease (GVHD) prophylaxis schedule with the exception of recipients of haploidentical marrow grafts, who received antithymocyte globulin after bone marrow transplantation as additional immunosuppression. There was no statistically significant difference in the rate of engraftment, or the cumulative incidences of acute and chronic GVHD between any of the 3 groups. The 2-year cumulative incidence of relapse was lower in matched unrelated patients (25%, P =.01) and mismatched unrelated patients (26%, P =.014) than in haploidentical patients (42%). Transplant-related mortality was significantly higher in recipients of mismatched unrelated grafts (45%, P =.01) and haploidentical grafts (42%, P =.001) compared with recipients of matched unrelated marrow grafts (23%). This resulted in a significantly higher probability of overall survival for matched unrelated patients (58%) versus either mismatched unrelated (34%, P =.01) or haploidentical (21%, P =.002) patients. There was no statistically significant difference in survival between patients who received mismatched unrelated grafts versus those who received haploidentical grafts. This study supports a donor selection algorithm whereby patients who lack a closely matched family donor be offered a phenotypically matched unrelated donor if available. There is no apparent advantage to using a mismatched unrelated versus a highly HLA-disparate family donor.